Suchen
Envista Holdings Corp
NVSTZur Watchlist hinzufügen
24.910USD
-0.350-1.39%
Handelsschluss 06/23, 16:00（ET）Kurse um 15 Minuten verzögert
4.11BMarktkapitalisierung
60.54KGV TTM
mehr Informationen über Envista Holdings Corp Unternehmen
Envista Holdings Corporation is a global dental products company. The Company's diversified portfolio of solutions covers a range of dentists' clinical needs for preventing, diagnosing, and treating dental conditions as well as improving the aesthetics of the human smile. It has more than 30 dental brands, including Nobel Biocare, Ormco, DEXIS and Kerr. Its segments include Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment primarily develops, manufactures and markets dental implant systems, including regenerative solutions, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. The Equipment & Consumables segment primarily develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems; and endodontic systems and related products.
Envista Holdings Corp Informationen
BörsenkürzelNVST
Name des UnternehmensEnvista Holdings Corp
IPO-datumSep 18, 2019
CEOKeel (Paul A)
Anzahl der mitarbeiter12300
WertpapierartOrdinary Share
GeschäftsjahresendeSep 18
Addresse200 S. Kraemer Blvd., Bldg. E
StadtBREA
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl92821
Telefon17148175418
Websitehttps://envistaco.com/en
BörsenkürzelNVST
IPO-datumSep 18, 2019
CEOKeel (Paul A)
Führungskräfte von Envista Holdings Corp
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Paul A. Keel
Mr. Paul A. Keel
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
154.81K
-8.28%
Mr. Stefan Nilsson
Mr. Stefan Nilsson
President - Nobel Biocare
President - Nobel Biocare
62.36K
+11.90%
Mr. Mark E. Nance
Mr. Mark E. Nance
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
56.88K
+9.83%
Ms. Wendy Carruthers
Ms. Wendy Carruthers
Independent Director
Independent Director
49.49K
+18.85%
Ms. Christine A. Tsingos
Ms. Christine A. Tsingos
Independent Director
Independent Director
49.48K
+18.86%
Mr. Daniel A. Raskas, J.D.
Mr. Daniel A. Raskas, J.D.
Independent Director
Independent Director
43.56K
+21.42%
Mr. Vivek Jain
Mr. Vivek Jain
Independent Director
Independent Director
42.49K
+21.96%
Ms. Veronica Acurio
Ms. Veronica Acurio
President - Orthodontics
President - Orthodontics
11.75K
-381.11%
Mr. Mischa M. Reis
Mr. Mischa M. Reis
Senior Vice President - Strategy and Corporate Development
Senior Vice President - Strategy and Corporate Development
--
--
Mr. R. Scott (Scott) Huennekens
Mr. R. Scott (Scott) Huennekens
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Paul A. Keel
Mr. Paul A. Keel
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
154.81K
-8.28%
Mr. Stefan Nilsson
Mr. Stefan Nilsson
President - Nobel Biocare
President - Nobel Biocare
62.36K
+11.90%
Mr. Mark E. Nance
Mr. Mark E. Nance
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
56.88K
+9.83%
Ms. Wendy Carruthers
Ms. Wendy Carruthers
Independent Director
Independent Director
49.49K
+18.85%
Ms. Christine A. Tsingos
Ms. Christine A. Tsingos
Independent Director
Independent Director
49.48K
+18.86%
Mr. Daniel A. Raskas, J.D.
Mr. Daniel A. Raskas, J.D.
Independent Director
Independent Director
43.56K
+21.42%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Envista Holdings Corp?
Die fünf größten Anteilseigner von Envista Holdings Corp sind: Mr. Paul A. Keel
Wie viele Institutionen halten Anteile an Envista Holdings Corp (NVST)?
Mit Stand vom 2026Q1 halten 711 Institutionen Anteile an Envista Holdings Corp, mit einem Gesamtmarktwert von etwa 203.45M, was 125.03% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -3285874.00 gestiegen.
